Avalo Therapeutics (AVTX) Debt Ratio (2014 - 2025)

Avalo Therapeutics (AVTX) has 9 years of Debt Ratio data on file, last reported at 0.29 in Q1 2023.

• Quarterly Debt Ratio fell 46.1% year-over-year to 0.29 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was 0.29 (down 46.1% YoY) and the FY2022 annual result came in at 0.4, down 1.26% from the prior year.
• Debt Ratio eased to 0.29 in Q1 2023, from 0.4 in the prior quarter.
• In the past five years, Debt Ratio ranged from a high of 0.58 in Q2 2022 to a low of 0.22 in Q1 2019.
• A 4-year average of 0.37 and a median of 0.34 in 2021 frame the typical range for Debt Ratio.
• Annual changes were most pronounced in 2022 — Debt Ratio soared 117.09% — and 2023, when it tumbled 46.1%.
• Tracing AVTX's Debt Ratio over 4 years: stood at 0.27 in 2019, then soared by 51.11% to 0.41 in 2021, then dropped by 1.26% to 0.4 in 2022, then decreased by 28.51% to 0.29 in 2023.
• The last three Debt Ratio figures came in at 0.29 (Q1 2023), 0.4 (Q4 2022), and 0.45 (Q3 2022), per Business Quant data.